User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

2273

Interactions with Platform & by Email *

INTERACTIONS

409

Unique # Participated *

PARTICIPANTS

68

Responses Validated *

VALIDATIONS

20

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Bare Metal Stents.....I-3
Drug Eluting Stents.....I-3
  
   Growth Revives as Drug Eluting Stents Bounce Back.....II-4
What’s Next on Cards in Coronary Stent Market?.....II-4
1$100
   Market Snapshots.....II-51$100
   Current and Future Analysis.....II-6
Drug Eluting Stents Steal the Show.....II-6
Star Player J&J to Quit DES Business in an Expensive Market Withdrawal.....II-6
2$125
   Drug Eluting Stent System – Safety Concerns.....II-8
Declining Prices – A Major Concern.....II-8
Restenosis - the Real Growth Driver.....II-8
1$100
   Small Vessels – A Major Cause of Restenosis.....II-9
Aging Population Propels Coronary Stent Market.....II-9
Next Generation Stents – A Boon for Treating Coronary Diseases.....II-9
Direct Stenting Systems Spur Growth.....II-9
1$100
   Drug Choice Impacts Market Entry.....II-10
Threats to Coronary Stents – Alternative Therapies/ Devices.....II-10
Cell Transplantation – A Major Threat to Coronary Stents.....II-10
Coronary Stents Market Challenged by Drug Therapy.....II-10
2$125
   Coronary Stents – Leading Players.....II-12
Table 1: Leading Players in the Global Coronary Stents Market (2010) - Percentage Breakdown of Market Share by Company - Boston Scientific, Abbott (Guidant), Johnson & Johnson, Medtronic, and Others (includes corresponding Graph/Chart).....II-12
1$350
   Bare Metal Stents – Leading Players.....II-13
Table 2: Leading Players in the Global Bare Metal Stents Market (2010) - Percentage Breakdown of Share for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart).....II-13
Drug-Eluting Stents – Leading Players.....II-13
Table 3: Global Drug Eluting Stents Market (2010): Percentage Breakdown of Share by Company - Boston Scientific, Abbott Labs, Johnson and Johnson, Medtronic, Others (includes corresponding Graph/Chart).....II-13
Major DES Types in the Market and Leading Manufacturers.....II-13
1$350
   Comparative Analysis of the Leading Players.....II-141$100
   Factors Responsible for Coronary Diseases.....II-15
Controllable Risk Factors.....II-15
High Blood Cholesterol.....II-15
Sedentary Life Style and Habits.....II-15
Smoking Habits.....II-15
1$100
   High Blood Pressure.....II-16
Uncontrollable Risk Factors.....II-16
Age.....II-16
Heredity.....II-16
Gender.....II-16
Causative Risk Factors.....II-16
Stress and Anger.....II-16
1$100
   Obesity.....II-17
Diabetes.....II-17
Symptoms of Coronary Artery Disease.....II-17
Diagnosis.....II-17
Treatment.....II-17
1$100
   Drug Supported Treatments.....II-18
Invasive Treatments.....II-18
Bypass Surgery.....II-18
Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty).....II-18
Natural Therapy.....II-18
1$100
   Coronary Angioplasty Suitable for Acute Myocardial Infarction.....II-19
Advancements in Coronary Disease Treatment Modalities.....II-19
University of Virginia’s Microbe Solution for Post Surgical Complications.....II-19
Radiation for Re-clogged Arteries Show Promise.....II-19
1$100
   Radioactive Coronary Stents Promise Bright Future.....II-201$100
   Introduction.....II-21
Evolution of Coronary Stents.....II-21
Applications of Coronary Stents.....II-21
1$100
   Stent Deployment.....II-221$100
   Key Stent Delivery Platforms by Select Company.....II-23
Coronary Stent Designs.....II-23
Key Factors Determining Coronary Stent Performance.....II-23
Delivery Convenience.....II-23
Efficient Scaffolding.....II-23
1$100
   Radiopacity (Visibility).....II-24
Optimum Flexibility.....II-24
Shape Conformability.....II-24
Material for Coronary Stent.....II-24
Risk Associated with Stenting.....II-24
1$100
   Improper Stent Implantation Likely Cause for In-Stent Restenosis.....II-25
Precautions.....II-25
1$100
   Direct Coronary Stenting – Creating an Enliven.....II-26
Limitations.....II-26
Regulatory Approvals Wooing Stent Market.....II-26
1$100
   A Peek into Regulatory Approvals for Coronary Stents.....II-272$200
   Bare Metal Stents.....II-29
Major Bare Metal Stents by Company.....II-29
Drug-Eluting Stents.....II-29
1$100
   DE Stents Overshadow Intravascular Brachytherapy Interventions.....II-30
Major Drug-Eluting Stents by Company.....II-30
Drugs for Coating DESs.....II-30
1$100
   Cytotoxic or Cytostatic Drug – the Debate Continues.....II-31
Dosing and Deliverability Crucial for DES.....II-31
Polymer Coatings for Effective Dosing and Deliverability.....II-31
Drugs Used for DES by Major Competitors in the Stent Market.....II-31
1$100
   Leading Coronary Stent Brands.....II-32
Cypher.....II-32
Structure and Delivery Mechanism.....II-32
Taxus.....II-32
1$100
   Structure and Delivery Mechanism.....II-331$100
   Extensive R&D Underway in Global Drug-Eluting Stents Market.....II-34
At the Labs.....II-34
Other Products Under Trials – A Recent Past Perspective.....II-34
OMT Developing R-stent.....II-34
Reva Developing Stainless Steel Bare-Metal Stent.....II-34
D&P Corp Developing Bovine Pericardium- Covered Stent.....II-34
1$100
   Advanced Bio Synthesizing Porous Drug- Eluting Stents.....II-35
Lombard Medical Developing PEP Coatings.....II-35
Shiga Develops Biodegradable Drug-Eluting Stent.....II-35
1$100
   Boston Scientific Launches ION™ Platinum Chromium Stent System.....II-36
Terumo Introduces Nobori Drug-Eluting Coronary Stent.....II-36
Boston Scientific Unveils TAXUS® Element™ and PROMUS® Element™ Stent Systems.....II-36
Covidien Introduces EverFlex+™ Self-Expanding Peripheral Stent System.....II-36
1$100
   Boston Scientific Launches Taxus Element Stent System in European Union.....II-37
Cordis Introduces PRESILLION™ PLUS Stent System in Europe.....II-37
Medtronic Launches Resolute Integrity Stent System.....II-37
1$100
   InspireMD Unveils MGuard Prime.....II-38
Boston Scientific Introduces Taxus Eluting Stent System.....II-38
Boston Scientific Unveils TAXUS Liberte Paclitaxel Eluting Stent System in
  Japan.....II-38
Alvimedica Launches Coracto Drug-Eluting Stent in Europe.....II-38
Abbott Labs to Launch XIENCE V in China.....II-38
1$100
   Medtronic Launches Driver Sprint RX Coronary STENT System.....II-39
Existent Introduces Premier Coronary Stent System.....II-39
Medtronic to Unveil Balloon Catheter Systems and Coronary Stents.....II-39
NanoInterventions Launches Mouse Stent Model.....II-39
InspireMD - MGuard™ Coronary Stent Launched in Italy.....II-39
1$100
   CeloNova BioSciences Launches CATANIA™ Coronary Stent with NanoThin
  Polyzene®-F.....II-40
Angiotech Launches Cook Medical’s Drug Eluting Zilver® PTX™ Stent in New
  Zealand.....II-40
1$100
   Boston Scientific Receives FDA Approval for Novel Paclitaxel-Eluting Coronary
  Stent.....II-41
Boston Scientific Receives Approval for Distribution of PROMUS® Everolimus-Eluting
  Stent.....II-41
Cordis Discontinues Production of NEVO™ Sirolimus- Eluting Coronary Stents.....II-41
Boston Scientific Receives FDA Approval for ION Stent.....II-41
1$100
   Abbott Obtains FDA Approval to Extend RX ACCULINK® Carotid Stent System
  Application.....II-42
Boston Scientific Receives CE Mark Approval for OMEGA™ Platinum Chromium Stent
  System.....II-42
Stentys Launches Stents across Additional Countries in Europe.....II-42
1$100
   Opto Circuits Acquires N.S. Remedies.....II-43
Biosensors International Group Takes Over Assets of Devax.....II-43
Cordis Signs Distribution Agreement with Ostial Solutions.....II-43
Medtronic Obtains FDA Approval for Integrity Coronary Stent System.....II-43
1$100
   Boston Scientific Receives Approval from Japanese MHLW for PROMUS® Coronary
  Stent.....II-44
InspireMD Selects Kirloskar Technologies for Distributing Coronary Stent
  Systems.....II-44
Boston Scientific Expands PROMUS® Everolimus- Eluting Coronary Stent System.....II-44
1$100
   Boston Scientific Receives TGS Approval from Australia.....II-45
Svelte Medical Systems Commences Clinical Trial of SOAW Delivery System.....II-45
Abbott Receives Japan's MHLW Approval for Xience V.....II-45
Opto Circuits Receives Mark Approval from Communite European.....II-45
Abbott Receives Health Canada Approval for XIENCE V® Stent System.....II-45
Medtronic Secures Japan's MHLW Approval for Endeavor® Drug Eluting Stent.....II-45
1$100
   Boston Scientific Takes Over Labcoat.....II-46
Micell and Maxcor Sign Strategic Agreement.....II-46
Cordis Receives FDA Approval for Variant of Cypher Sirolimus-Eluting Coronary
  Stent.....II-46
Boston Scientific Obtains CE Mark Approval for Promus Element Everolimus-Eluting
  Coronary Stent System.....II-46
Cypher Select® Plus Sirolimus-eluting Coronary Stent Gains CE Mark for Treatment in
  Diabetic Patients.....II-46
1$100
   Atrium Medical Obtains CE Mark for Cinatra™.....II-47
Medtronic Secures CE Mark Approval for Endeavor Drug-Eluting Stent for Use in Treatment
  of ACS.....II-47
CorNova® Obtains CE mark approval for Valecor Platinum Coronary Stent System.....II-47
Cook Medical Receives CE Mark Approval and Launches Zilver® PTX® Drug-Eluting
  Peripheral Stent.....II-47
Disa Receives CE Approval for Coronary Stent.....II-47
1$100
   Datascope Acquires Peripheral Stent Business of Sorin Group.....II-48
Boston Scientific Receives FDA approval for TAXUS® Liberte® Drug-Eluting STENT.....II-48
Abbott Labs Receives FDA Approval for Xience V.....II-48
Bard to Purchase Assets of LifeStent Product Portfolio.....II-48
Medtronic Receives the US FDA Approval to Use Endeavor® Stent.....II-48
1$100
   Medtronic Inc. Receives Approval for its Drug-Eluting Stent, “Endeavor” In
  Canada.....II-49
Boston Scientific to Market TAXUS® Liberte® Stent System in Canada.....II-49
Abbott Applies for Approval of XIENCE™ V in Japan.....II-49
Medinol Achieves CE Mark Approval for Presillion™ Cobalt Chromium Coronary Stent
  System.....II-49
1$100
   Iberhospitex Receives Spanish Approval to Sell Palau Pharma’s “Active” Coronary
  Stent.....II-50
Clearstream’s Intrepide Drug Eluting Stent of Clearstream Receives CE mark
  approval.....II-50
Terumo Introduces Its Drug-Eluting Stent in Germany and Marks Its European
  Entry.....II-50
Tryton Medical’s Side-Branch Stent Achieves CE Mark Approval.....II-50
CV Therapeutics Offers its Stent Coating Technology to Medlogics Device
  Corporation.....II-50
1$100
   Abbott’s 2.25mm-Sized XIENCE™ V Drug Eluting Stent receives CE Mark of
  Approval.....II-51
Biosensors Receives CE Mark Approval for BioMatrix® Stent System.....II-51
Nfocus Neuromedical’s CardioVasc™ Stent-Graft and Delivery System Receives CE Mark
  Approval.....II-51
1$100
   Angiotech Pharmaceuticals (Canada).....II-52
Abbott Vascular (USA).....II-52
Biosensors International (USA).....II-52
1$100
   Boston Scientific Corp. (USA).....II-53
Cordis Corporation (JNJ) - (USA).....II-53
Medtronic, Inc. (USA).....II-53
1$100
   Medtronic Cardiovascular, Inc. (USA).....II-54
OrbusNeich (Hong Kong).....II-54
Terumo Europe N.V. (Belgium).....II-54
1$100
   Table 4: World Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-551$350
   Table 5: World Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-561$350
   Table 6: World Historic Review for Coronary Stents by Geographic Region - US, Japan, Europe, Asia- Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-571$350
   Table 7: World Historic Review for Coronary Stents by Geographic Region - US, Japan, Europe, Asia- Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-581$350
   Table 8: World 15-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-591$350
   Table 9: World 15-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-601$350
   Table 10: World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-611$350
   Table 11: World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-621$350
   Table 12: World Historic Review for Coronary Stents by Product Segment-Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-631$350
   Table 13: World Historic Review for Coronary Stents by Product Segment-Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-641$350
   Table 14: World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-651$350
   Table 15: World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-661$350
   Table 16: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-671$350
   Table 17: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-681$350
   Table 18: World Historic Review for Bare Metal Stents By Geographic Region - US, Japan, Europe, Asia- Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-691$350
   Table 19: World Historic Review for Bare Metal Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-701$350
   Table 20: World 15-Year Perspective for Bare Metal Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-711$350
   Table 21: World 15-Year Perspective for Bare Metal Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-721$350
   Table 22: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-731$350
   Table 23: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-741$350
   Table 24: World Historic Review for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-751$350
   Table 25: World Historic Review for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-761$350
   Table 26: World 15-Year Perspective for Drug Eluting Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-771$350
   Table 27: World 15-Year Perspective for Drug Eluting Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-781$350
   A. Market Analysis.....II-79
Largest Market Worldwide.....II-79
Coronary Artery Disease - A US Perspective.....II-79
Baby Boomers Boost Coronary Stent Market.....II-79
Revival in the DES Market.....II-79
1$100
   Reimbursement System.....II-80
National Average Medicare Payment For DRGS.....II-80
Competitive Scenario.....II-80
Leading Players.....II-80
Coronary Stents – Boston Scientific and JNJ Battle for Dominance.....II-80
1$100
   Table 28: Leading Players in the US Coronary Stents Market (2010) - Percentage Breakdown of Share for Boston Scientific, Abbott and Johnson & Johnson (includes corresponding Graph/Chart).....II-81
Drug Eluting Stents – Competition in the Brewing.....II-81
Table 29: Leading Players in the US Drug -Eluting Stents Market (2010) - Percentage Breakdown of share for Boston Scientific, Abbott Labs, J&J-Cordis and Medtronic (includes corresponding Graph/Chart).....II-81
1$350
   Regulatory Environment.....II-82
B. Market Analytics.....II-82
Table 30: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-82
1$350
   Table 31: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-831$350
   Table 32: US Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-841$350
   Table 33: US Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-851$350
   Table 34: US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-861$350
   Table 35: US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-871$350
   A. Market Analysis.....II-88
Prospects Weighed down by Regulatory Entanglements.....II-88
Japanese Coronary Stents Command Higher Prices.....II-88
Table 36: Coronary Stent Pricing (2008): Comparative Analysis of Prices in Japan, US, Europe and Global Average (includes corresponding Graph/Chart).....II-88
1$350
   Competitive Landscape.....II-89
Table 37: Leading Players in the Japanese Coronary Stent Market (2010) - Percentage Breakdown of Share for Johnson & Johnson, Medtronic, Boston Scientific, and Others (includes corresponding Graph/Chart).....II-89
1$350
   Table 38: Leading Players in the Japanese Bare Metal Stent Market (2010) - Percentage Breakdown of Share for Medtronic, Boston Scientific, JNJ and Others (includes corresponding Graph/Chart).....II-90

Table 39: Leading Players in Japanese Drug- Eluting Stent Market (2010) - Percentage Breakdown of Share for Johnson & Johnson and Boston Scientific (includes corresponding Graph/Chart).....II-90
1$350
   B. Market Analytics.....II-91
Table 40: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-91
1$350
   Table 41: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-921$350
   Table 42: Japanese Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-931$350
   Table 43: Japanese Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-941$350
   Table 44: Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-951$350
   Table 45: Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-961$350
   A. Market Analysis.....II-97
Cardiovascular Disease in Europe – A Perspective.....II-97
Growth Bar Too Low.....II-97
Two-Speed Europe.....II-97
1$100
   Stent Market’s Merger Mania.....II-98
Dampeners to Rapid Adoption of DES in Europe.....II-98
1$100
   Competitive Scenario.....II-99
Table 46: Leading Players in the European Drug- Eluting Stent Market (2010) - Percentage Breakdown of Share for Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart).....II-99
1$350
   B. Market Analytics.....II-100
Table 47: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-100
1$350
   Table 48: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1011$350
   Table 49: European Historic Review for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1021$350
   Table 50: European Historic Review for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1031$350
   Table 51: European 15-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1041$350
   Table 52: European 15-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2075 (includes corresponding Graph/Chart).....II-1051$350
   Table 53: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1061$350
   Table 54: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1071$350
   Table 55: European Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1081$350
   Table 56: European Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1091$350
   Table 57: European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1101$350
   Table 58: European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1111$350
   Market Analysis.....II-112
Table 59: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-112
1$350
   Table 60: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1131$350
   Table 61: French Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1141$350
   Table 62: French Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1151$350
   Table 63: French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1161$350
   Table 64: French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1171$350
   Market Analysis.....II-118
Table 65: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-118
1$350
   Table 66: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1191$350
   Table 67: German Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1201$350
   Table 68: German Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1211$350
   Table 69: German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1221$350
   Table 70: German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1231$350
   Market Analysis.....II-124
Table 71: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-124
1$350
   Table 72: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1251$350
   Table 73: Italian Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1261$350
   Table 74: Italian Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1271$350
   Table 75: Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1281$350
   Table 76: Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1291$350
   Market Analysis.....II-130
Table 77: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-130
1$350
   Table 78: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1311$350
   Table 79: UK Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1321$350
   Table 80: UK Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1331$350
   Table 81: UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1341$350
   Table 82: UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1351$350
   Market Analysis.....II-136
Table 83: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-136
1$350
   Table 84: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1371$350
   Table 85: Spanish Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1381$350
   Table 86: Spanish Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1391$350
   Table 87: Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1401$350
   Table 88: Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1411$350
   Market Analysis.....II-142
Table 89: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-142
1$350
   Table 90: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1431$350
   Table 91: Russian Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1441$350
   Table 92: Russian Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1451$350
   Table 93: Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1461$350
   Table 94: Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1471$350
   Market Analysis.....II-148
Table 95: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-148
1$350
   Table 96: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1491$350
   Table 97: Rest of Europe Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1501$350
   Table 98: Rest of Europe Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1511$350
   Table 99: Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1521$350
   Table 100: Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1531$350
   A. Market Analysis.....II-154
China – Healthcare Reforms to Propel DES Market.....II-154
Table 101: Coronary Stent Market in China (2010): Percentage Breakdown of Market Share by Company- Shanghai Microport, Beijing Lepu, JW Medical, J&J Cordis, Medtronic and Others (includes corresponding Graph/Chart).....II-154
1$350
   Coronary Stent Market in a Bubble Zone Now.....II-155
Regional Players and their DES Development Efforts.....II-155
Cost Focus Helps Stent Makers Win the Market Stunt.....II-155
1$100
   B. Market Analytics.....II-156
Table 102: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-156
1$350
   Table 103: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1571$350
   Table 104: Asia-Pacific Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1581$350
   Table 105: Asia-Pacific Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008(includes corresponding Graph/Chart).....II-1591$350
   Table 106: Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1601$350
   Table 107: Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1611$350
   A. Market Analysis.....II-162
Brazil – Low Penetration of DES.....II-162
South Africa – Leading Players.....II-162
Table 108: Leading Players in South African Coronary Stent Market (2010) - Percentage Breakdown by Unit Sales for Johnson & Johnson, Boston Scientific, Guidant, Abbott and Others (includes corresponding Graph/Chart).....II-162
1$350
   B. Market Analytics.....II-163
Table 109: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).....II-163
1$350
   Table 110: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).....II-1641$350
   Table 111: Rest of World Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1651$350
   Table 112: Rest of World Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).....II-1661$350
   Table 113: Rest of World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1671$350
   Table 114: Rest of World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1681$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com